CONTENTS

SPECIAL SECTION ON PHARMACOKINETIC AND DRUG METABOLISM PROPERTIES OF NOVEL THERAPEUTIC MODALITIES

Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities. Brooke M. Rock and Robert S. Foti .......................... 1097

Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides. Amita Datta-Mannan ............ 1100


Effect of Size on Solid Tumor Disposition of Protein Therapeutics. Zhe Li, Yingyi Li, Hsuan-Ping Chang, Hsueh-Yuan Chang, Leiming Guo, and Dhaval K. Shah ............................ 1136

Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. Donglu Zhang, Peter S. Dragovich, Shang-Fan Yu, Yong Ma, Thomas H. Pillow, Jack D. Sadowsky, Dian Su, Wei Wang, Andrew Polson, S. Cyrus Khojasteh, and Cornelis E.C.A. Hop ............................................. 1146


Metabolism and Disposition of Volanesorsen, a 2′-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Noah Post, Rosie Yu, Sarah Greenlee, Hans Gaus, Eunju Hurh, John Matson, and Yanfeng Wang ............................................. 1164

Plasma and Liver Protein Binding of N-Acetylgalactosamine–Conjugated Small Interfering RNA. Sara C. Humphreys, Mai B. Thayer, Julie M. Lade, Bin Wu, Kelvin Sham, Babak Basiri, Yue Hao, Xin Huang, Richard Smith, and Brooke M. Rock ............................................. 1174

In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters. Diane Ramsden, Jing-Tao Wu, Brad Zerler, Sajida Iqbal, Jim Jiang, Valerie Clausen, Krishna Aluri, Yongli Gu, Sean Dennin, Joohwan Kim, and Saeho Chong .................. 1183

SYNTHESIS AND CHARACTERIZATION OF BODIPY-FL-CYCLOSPORINE A AS A SUBSTRATE FOR MULTIDRUG RESISTANCE-LINKED P-GLYCOPROTEIN (ABCB1). Andaleeb Sajid, Natarajan Raju, Sabrina Lusvarghi, Shahrooz Vahedi, Rolf E. Swenson, and Suresh V. Ambudkar .................................................. 1013

CANINE ALBUMIN POLYMORPHISMS AND THEIR IMPACT ON DRUG PLASMA PROTEIN BINDING. Ana P. Costa, Michael H. Court, Neal S. Burke, Zhaohui Zhu, Katrina L. Mealey, and Nicolas F. Villarino .................................................. 1024

Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax
Contents (cont’d.)

Human Hepatocytes. Veera Raghava Choudary Palacharla, Prathyusha Chunduru, Devender Reddy Ajjala, Gopinadh Bhyrapuneni, Ramakrishna Nirogi, and Albert P. Li .................................................. 1032

Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes. Wilasinee Dunkoksung, Nontima Vardhamabhati, Pongpun Siripong, and Suree Jianmongkol .............................................................. 1040


Mechanism of H₂S Formation from the Metabolism of Anetholedithiolethione and Anetholedithiolone by Rat Liver Microsomes. Martin Dulac, Citra Nagarathinam, Patrick Dansette, Daniel Mansuy, and Jean-Luc Boucher ................................................................. 1061

Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters. Zhongjian Wang, Hanyu Yang, Jiong Xu, Kaijing Zhao, Yang Chen, Limin Liang, Ping Li, Nan Chen, Donghao Geng, Xiangping Zhang, Xiaodong Liu, and Li Liu ................................................................. 1066

Identification and Characterization of Efflux Transporters That Modulate the Subtoxic Disposition of Diclofenac and Its Metabolites. Renato J. Scialis, Lauren M. Aleksunes, Iván L. Csanaky, Curtis D. Klaassen, and José E. Manautou ................................................................. 1080

Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. Pan-Fen Wang, Alicia Neiner, and Evan D. Kharasch 1195


SHORT COMMUNICATION

The 2-Hydroxyiminostilbene Metabolite of Carbamazepine or the Supernatant from Incubation of Hepatocytes with Carbamazepine Activates Inflammasomes: Implications for Carbamazepine-Induced Hypersensitivity Reactions. Ryuji Kato, Yoshio Ijiri, Tetsuya Hayashi, and Jack Uetrecht 1093

ERRATUM

Correction to “Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry” . . . 1231

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Enzymatic Disulfide Bond Cleavage. See the article by Zhang et al. (dx.doi.org/10.1124/dmd.118.086132).